If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Although world is not on track to end AIDS by 2030 but it is no less than a miracle when we take into account the scientific ...

In a sweeping national overhaul of HIV prevention funding, the CDC chose to bypass local and statewide community organizations like AVOL Kentucky.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Dozens of HIV experts at the Centers for Disease Control and Prevention received emails earlier in June revoking notices they received 10 weeks ago that laid them off. Damage to their projects may ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many ...

The Trump administration's budget proposal for 2026 looks to make cuts to HIV prevention in clinics and community organizations.

Updated CDC guidelines on PEP after nonoccupational HIV exposure address newer ART agents and clinical considerations for patients with a history of long-acting ART.